Double-blind randomized study to compare the efficacy and safety of tamsulosin prolonged release tablet 0.4 mg with Harnal capsule 0.2 mg in patients with lower urinary tract symptoms (LUTS) associated with benign prostate hyperplasia (BPH)

INTERVENTION: Intervention name : tamsulosin prolonged release tablets Dosage And administration of the intervention : oral Control intervention name : tamsulosin sustained release capsule Dosage And administration of the control intervention : oral CONDITION: Lower urinary tract symptoms, Benign prostate hyperplasia PRIMARY OUTCOME: Change in total I‐PSS SECONDARY OUTCOME: Change in individual I‐PSS INCLUSION CRITERIA: A total I‐PSS of 8 to 30 A maximum flow rate in range of 5‐15 ml/s; Voided volume of 150 ml or over Residual volume of 100ml or less Prostate volume of 20ml or over